Skip to main content
Top
Published in: BMC Infectious Diseases 1/2021

Open Access 01-12-2021 | Anemia | Research article

Hematological profiles of visceral leishmaniasis patients before and after treatment of anti-leishmanial drugs at University of Gondar Hospital; Leishmania Research and Treatment Center Northwest, Ethiopia

Authors: Elias Shiferaw, Fadil Murad, Mitikie Tigabie, Mareye Abebaw, Tadele Alemu, Sefanit Abate, Rezika Mohammed, Arega Yeshanew, Fitsumbrhan Tajebe

Published in: BMC Infectious Diseases | Issue 1/2021

Login to get access

Abstract

Background

Visceral leshimaniasis is a parasitic disease characterized by systemic infection of phagocytic cells and an intense inflammatory response. The progression of the disease or treatment may have an effect on hematological parameters of these patients'. Thus, the current study sought to compare the hematological profiles of visceral leishmaniasis patients before and after treatment with anti-leishmaniasis drugs.

Method

An institutional-based retrospective cohort study was conducted among visceral leishmaniasis patients admitted to the University of Gondar comprehensive specialized referral hospital leishmaniasis research and treatment centre between September 2013 and August 2018. Hematological profiles were extracted from the laboratory registration book before and after treatment. Data were entered to Epi-info and exported to SPSS for analysis. Descriptive statistics were summarized using frequency and percentage to present with the table. The mean, standard deviation, median, and interquartile range were used to present the data. Furthermore, using the paired t-test and the Wilcoxon Signed rank test, the mean difference for normally and non-normally distributed data was compared. Spearman and Pearson correlation analysis were used to describe the relationship between hematological parameters and various variables. A P value of 0.05 was considered statistically significant.

Result

With the exception of the absolute neutrophil count, all post-treatment hematological parameters show a significant increase when compared to pre-treatment levels. Prior to treatment, the prevalence of anemia, leukopenia, and thrombocytopenia was 85.5, 83.4, and 75.8%, respectively, whereas it was 58.3, 38.2, and 19.2% following treatment. Furthermore, parasite load was found to have a statistically significant negative correlation with hematological profiles, specifically with white blood cell and red blood cell parameters.

Conclusion

According to our findings, patients with visceral leishmaniasis had improved hematological profiles after treatment. The effect of treatment on parasite proliferation and concentration within visceral organs, in which the parasite load could directly affect the patient's hematological profiles, may be associated with the change in hematological profiles.
Literature
1.
go back to reference Leta S, Dao THT, Mesele F, Alemayehu G. Visceral leishmaniasis in Ethiopia: an evolving disease. PLoS Negl Trop Dis. 2014;8(9):e3131.CrossRef Leta S, Dao THT, Mesele F, Alemayehu G. Visceral leishmaniasis in Ethiopia: an evolving disease. PLoS Negl Trop Dis. 2014;8(9):e3131.CrossRef
2.
go back to reference Hotez PJ, Kamath A. Neglected tropical diseases in sub-Saharan Africa: review of their prevalence, distribution, and disease burden. PLoS Negl Trop Dis. 2009;3(8):e412.CrossRef Hotez PJ, Kamath A. Neglected tropical diseases in sub-Saharan Africa: review of their prevalence, distribution, and disease burden. PLoS Negl Trop Dis. 2009;3(8):e412.CrossRef
3.
go back to reference Mehdi DS. The effect of visceral leishmaniasis on some liver enzyme and blood parameter. J Thiqar Univ. 2008;4:2–5. Mehdi DS. The effect of visceral leishmaniasis on some liver enzyme and blood parameter. J Thiqar Univ. 2008;4:2–5.
4.
go back to reference Motuma K, Abera E, Wondu B, Negash A. Visceral Leishmaniasis in Ethiopia: A Review. Eur J Biol Sci. 2016;8(2):70–8. Motuma K, Abera E, Wondu B, Negash A. Visceral Leishmaniasis in Ethiopia: A Review. Eur J Biol Sci. 2016;8(2):70–8.
5.
go back to reference El-Safi AES, Adm ASK, Hamza KM. Hematological profile of patients with visceral leishmaniasis at Al-Gaderf State—Sudan. Clin Med. 2016;2(3):31–9. El-Safi AES, Adm ASK, Hamza KM. Hematological profile of patients with visceral leishmaniasis at Al-Gaderf State—Sudan. Clin Med. 2016;2(3):31–9.
7.
go back to reference Middib MM, Mouktar FAA. Hematological changes including the immune system in patients with visceral leshmaniasis at Al-Muthanna governorate. J Babylon Uni Pure Appl Sci. 2014;4(22). Middib MM, Mouktar FAA. Hematological changes including the immune system in patients with visceral leshmaniasis at Al-Muthanna governorate. J Babylon Uni Pure Appl Sci. 2014;4(22).
8.
go back to reference Al-Ghazaly J, Al-Dubai W, Abdullah M, Al-Gharasi L. Hematological characteristics of yemeni adults and children with visceral leishmaniasis could eosinopenia be a suspicion index? Mediterr J Hematol Infect Dis. 2017;9(1):1–8.CrossRef Al-Ghazaly J, Al-Dubai W, Abdullah M, Al-Gharasi L. Hematological characteristics of yemeni adults and children with visceral leishmaniasis could eosinopenia be a suspicion index? Mediterr J Hematol Infect Dis. 2017;9(1):1–8.CrossRef
9.
go back to reference Tesfaye E, Fissehatsion K, Terefe B, Enawgaw B. Haematological Abnormalities in Visceral Leishmaniasis Patients Attending Gondar University Hospital; Retrospective Study. IJHPEBS. 2017;3(5):48–53.CrossRef Tesfaye E, Fissehatsion K, Terefe B, Enawgaw B. Haematological Abnormalities in Visceral Leishmaniasis Patients Attending Gondar University Hospital; Retrospective Study. IJHPEBS. 2017;3(5):48–53.CrossRef
10.
go back to reference Varma N, Naseem S. Hematologic changes in visceral leishmaniasis/kala azar. Indian J Hematol Blood Transfus. 2010;26(3):78–82.CrossRef Varma N, Naseem S. Hematologic changes in visceral leishmaniasis/kala azar. Indian J Hematol Blood Transfus. 2010;26(3):78–82.CrossRef
11.
go back to reference Ethiopia Ministery of Ethiopia. Guideline for diagnosis, treatment and prevention of leishmaniasis in Ethiopia. Ethiopia: Ethiopian Ministry of Health; 2013. Ethiopia Ministery of Ethiopia. Guideline for diagnosis, treatment and prevention of leishmaniasis in Ethiopia. Ethiopia: Ethiopian Ministry of Health; 2013.
12.
go back to reference Central Statistical Agency. The 2007 population and housing census of Ethiopia. Ethiopia: Central Statistical Agency Addis Abeba; 2008. Central Statistical Agency. The 2007 population and housing census of Ethiopia. Ethiopia: Central Statistical Agency Addis Abeba; 2008.
13.
go back to reference Yalew A, Terefe B, Alem M, Enawgaw B. Hematological reference intervals determination in adults at Gondar university hospital, Northwest Ethiopia. BMC Res Notes. 2016;9(1):483.CrossRef Yalew A, Terefe B, Alem M, Enawgaw B. Hematological reference intervals determination in adults at Gondar university hospital, Northwest Ethiopia. BMC Res Notes. 2016;9(1):483.CrossRef
14.
go back to reference Leta S, Dao THT, Mesele F, Alemayehu G. Visceral leishmaniasis in ethiopia: an evolving disease. PLoS Negl Trop Dis. 2014;8(9):1–7.CrossRef Leta S, Dao THT, Mesele F, Alemayehu G. Visceral leishmaniasis in ethiopia: an evolving disease. PLoS Negl Trop Dis. 2014;8(9):1–7.CrossRef
15.
go back to reference Sarkari B, Naraki T, Ghatee MA, Khabisi SA, Davami MH. Visceral leishmaniasis in Southwestern Iran: a retrospective clinico-hematological analysis of 380 consecutive hospitalized cases (1999–2014). PLoS ONE. 2016;11(3):1–8.CrossRef Sarkari B, Naraki T, Ghatee MA, Khabisi SA, Davami MH. Visceral leishmaniasis in Southwestern Iran: a retrospective clinico-hematological analysis of 380 consecutive hospitalized cases (1999–2014). PLoS ONE. 2016;11(3):1–8.CrossRef
16.
go back to reference Agrawal Y, Sinha A, Upadhyaya P, Kafle S, Rijal S, Khanal B. Hematological profile in visceral leishmaniasis. Int J Infect Microbiol. 2013;2(2):39–44.CrossRef Agrawal Y, Sinha A, Upadhyaya P, Kafle S, Rijal S, Khanal B. Hematological profile in visceral leishmaniasis. Int J Infect Microbiol. 2013;2(2):39–44.CrossRef
17.
go back to reference Mulaw T, Tariku A, Tsegaye AT, Abebe Z. Effect of iron-folic acid supplementation on change of hemoglobin among visceral Leishmaniasis patients in northwest Ethiopia: a retrospective follow up study. BMC Hematol. 2018;18(29):2–7. Mulaw T, Tariku A, Tsegaye AT, Abebe Z. Effect of iron-folic acid supplementation on change of hemoglobin among visceral Leishmaniasis patients in northwest Ethiopia: a retrospective follow up study. BMC Hematol. 2018;18(29):2–7.
19.
go back to reference Gupta N, Kamla K, Mirdha BR. Clinical and laboratory analysis of patients with leishmaniasis: a retrospective study from a tertiary care center in New Delhi. Iran J Parasitol. 2017;12(4):632.PubMedPubMedCentral Gupta N, Kamla K, Mirdha BR. Clinical and laboratory analysis of patients with leishmaniasis: a retrospective study from a tertiary care center in New Delhi. Iran J Parasitol. 2017;12(4):632.PubMedPubMedCentral
20.
go back to reference Carvalho S, Cruz T, Santarém N, Castro H, Costa V, Tomás AM. Heme as a source of iron to Leishmania infantum amastigotes. Acta Trop. 2009;109:131–5.CrossRef Carvalho S, Cruz T, Santarém N, Castro H, Costa V, Tomás AM. Heme as a source of iron to Leishmania infantum amastigotes. Acta Trop. 2009;109:131–5.CrossRef
21.
go back to reference Das NK, Biswas S, Solanki S, Mukhopadhyay CK. Leishmania donovani depletes labile iron pool to exploit iron uptake capacity of macrophage for its intracellular growth. Cell Microbiol. 2009;11(1):83–94.CrossRef Das NK, Biswas S, Solanki S, Mukhopadhyay CK. Leishmania donovani depletes labile iron pool to exploit iron uptake capacity of macrophage for its intracellular growth. Cell Microbiol. 2009;11(1):83–94.CrossRef
22.
go back to reference Saurabh K, Ranjan S, Prasad RR. Clinical and haematological parameters associated with patients of visceral leishmaniasis in a district of North Bihar. Int J Community Med Public Health. 2017;4(6):1957–60.CrossRef Saurabh K, Ranjan S, Prasad RR. Clinical and haematological parameters associated with patients of visceral leishmaniasis in a district of North Bihar. Int J Community Med Public Health. 2017;4(6):1957–60.CrossRef
23.
go back to reference An I, Harman M, Esen M, Çelik H. The effect of pentavalent antimonial compounds used in the treatment of cutaneous leishmaniasis on hemogram and biochemical parameters. Cutan Ocul Toxicol. 2019;38(3):294–7.CrossRef An I, Harman M, Esen M, Çelik H. The effect of pentavalent antimonial compounds used in the treatment of cutaneous leishmaniasis on hemogram and biochemical parameters. Cutan Ocul Toxicol. 2019;38(3):294–7.CrossRef
24.
go back to reference Singh OP, Singh B, Chakravarty J, Sundar S. Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective. Infect Dis Poverty. 2016;5(19):2–15. Singh OP, Singh B, Chakravarty J, Sundar S. Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective. Infect Dis Poverty. 2016;5(19):2–15.
Metadata
Title
Hematological profiles of visceral leishmaniasis patients before and after treatment of anti-leishmanial drugs at University of Gondar Hospital; Leishmania Research and Treatment Center Northwest, Ethiopia
Authors
Elias Shiferaw
Fadil Murad
Mitikie Tigabie
Mareye Abebaw
Tadele Alemu
Sefanit Abate
Rezika Mohammed
Arega Yeshanew
Fitsumbrhan Tajebe
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2021
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-021-06691-7

Other articles of this Issue 1/2021

BMC Infectious Diseases 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.